While radiosensitizing chemotherapy has improved survival for several types of cancer, current chemoradiation regimens remain ineffective for many patients and have substantial toxicities. Given the strong need for the development of novel radiosensitizers to further improve patient outcomes, the Radiation Research Program (RRP) and the Small Business Innovation Research (SBIR) in the National Cancer Institute (NCI) issued a Request for Proposals (RFP) through the NCI SBIR Development Center's contracts pathway. We sought to determine the research outcomes for the NCI SBIR Development Center's funded proposals for the development of radiosensitizers. We identified SBIR-funded contracts and grants for the development of radiosensitizers from 2009 to 2018 using the National Institutes of Health (NIH) Reporter database. Research outcomes of the NCI SBIR Development Center-funded proposals were determined using a comprehensive internet search. We searched PubMed, clinicaltrials.gov, company websites and google.com for research articles, abstracts and posters, clinical trials, press releases and other news, related to progress in the development of funded radiosensitizers. To protect the intellectual property of the investigators and small businesses, all information obtained and reported is publicly available. The SBIR Program has funded four contracts and 11 grants for the development of novel radiosensitizers. Two companies have received phase IIb bridge awards. Overall, 50% of companies (6/12) have successfully advanced their investigational drugs into prospective clinical trials in cancer patients, and all but one company are investigating their drug in combination with radiation therapy as described in the NCI SBIR Development Center proposal. To date, only one company has initiated a randomized trial of standard of care with or without their radiosensitizer. In conclusion, the NCI SBIR Development Center has funded the development of novel radiosensitizers leading to clinical trials of novel drugs in combination with radiation therapy. Continued follow-up is needed to determine if any of these novel radiosensitizers produce improved tumor control and/or overall survival.

中文翻译：

---

通过国家癌症研究所的小型企业创新研究计划开发新型放射增敏剂。

虽然放射增敏化疗提高了几种癌症的生存率，但目前的放化疗方案对许多患者仍然无效，并且具有相当大的毒性。鉴于对开发新型放射增敏剂以进一步改善患者预后的强烈需求，美国国家癌症研究所 (NCI) 的放射研究计划 (RRP) 和小型企业创新研究 (SBIR) 通过NCI SBIR 开发中心的合同途径。我们试图确定 NCI SBIR 开发中心资助的放射增敏剂开发提案的研究成果。我们使用美国国立卫生研究院 (NIH) 报告数据库确定了 2009 年至 2018 年 SBIR 资助的用于开发放射增敏剂的合同和赠款。NCI SBIR 发展中心资助的提案的研究成果是使用全面的互联网搜索确定的。我们在 PubMed、clinicaltrials.gov、公司网站和 google.com 上搜索了与受资助的放射增敏剂开发进展相关的研究文章、摘要和海报、临床试验、新闻稿和其他新闻。为了保护调查人员和小企业的知识产权，所有获得和报告的信息都是公开的。SBIR 计划资助了四份合同和 11 份赠款，用于开发新型放射增敏剂。两家公司获得了 IIb 期桥梁奖。总体而言，50% 的公司 (6/12) 已成功将其研究药物推进癌症患者的前瞻性临床试验，除了一家公司外，所有公司都在研究他们的药物与放射疗法的结合，如 NCI SBIR 开发中心提案中所述。迄今为止，只有一家公司发起了一项关于有或没有放射增敏剂的标准护理的随机试验。总之，NCI SBIR 开发中心资助了新型放射增敏剂的开发，导致新型药物与放射治疗相结合的临床试验。需要继续随访以确定这些新型放射增敏剂中的任何一种是否能改善肿瘤控制和/或总体存活率。NCI SBIR 开发中心资助了新型放射增敏剂的开发，导致新型药物与放射治疗相结合的临床试验。需要继续随访以确定这些新型放射增敏剂中的任何一种是否能改善肿瘤控制和/或总体存活率。NCI SBIR 开发中心资助了新型放射增敏剂的开发，导致新型药物与放射治疗相结合的临床试验。需要继续随访以确定这些新型放射增敏剂中的任何一种是否能改善肿瘤控制和/或总体存活率。